Phathom Pharmaceuticals brings relief to millions with the inclusion of its drug VOQUEZNA in Express Scripts’ national formularies
Phathom Pharmaceuticals announced that its innovative treatment for Erosive Esophagitis, a form of gastroesophageal reflux disease (GERD), is now accessible to an estimated 60 million individuals in the United States. VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), marks a major milestone in the field of Erosive GERD treatment. It represents the first new class of treatment for Erosive GERD to be made available in the U.S. in over 30 years. This breakthrough drug is sure to revolutionize the landscape of GERD treatment options.
Chief Commercial Officer of Phathom, Martin Gilligan, expressed his enthusiasm about the inclusion of VOQUEZNA in Express Scripts’ national formularies. He emphasized that this move provides millions of GERD patients with immediate access to a novel and effective treatment option like never before.
The decision to include VOQUEZNA in Express Scripts’ formularies is in direct response to the high level of dissatisfaction among both patients and prescribers with existing treatments for Erosive GERD. With approximately 20 million people in the U.S. affected by Erosive GERD, it is alarming that 35% of patients treated with a prescription PPI switch to a different PPI within three months of initial treatment, according to medical claims analysis.
Phathom Pharmaceuticals is offering co-pay assistance programs for eligible patients with commercial insurance. This commitment to patient access ensures that cost will not be a barrier to receiving this ground-breaking treatment for Erosive GERD.
Phathom Pharmaceuticals is not stopping there. The company is actively working to increase coverage for VOQUEZNA by engaging with other major PBMs and health plans. Their dedication to expanding access to this life-changing treatment reflects their commitment to improving the lives of patients suffering from Erosive GERD.
It is important to note that VOQUEZNA is marketed exclusively by Phathom Pharmaceuticals and is only available by prescription. Patients interested in exploring this new treatment option should consult their healthcare providers to see if VOQUEZNA is right for them.
Phathom Pharmaceuticals’ inclusion of VOQUEZNA in Express Scripts’ national formularies is a significant step forward in addressing the unmet needs of Erosive GERD patients. With millions now having access to a groundbreaking treatment option, Phathom Pharmaceuticals is poised to make a lasting impact on the field of gastroesophageal reflux disease treatment.
Analyst comment
Positive news. The inclusion of Phathom Pharmaceuticals’ drug VOQUEZNA in Express Scripts’ national formularies is expected to have a positive impact on the market. With immediate access to this innovative treatment option, millions of GERD patients will benefit. Phathom’s commitment to expanding coverage and affordability further strengthens its position in the market.
